Global Primary Aldosteronism Market Size, Share, Forecast Report, 2020-2027

The adrenal glands within the body produce some essential hormones like aldosterone. This hormone balances the levels of sodium and potassium in the blood. Primary aldosteronism is a medical condition in which the adrenal glands produce high levels of aldosterone, causing the patient to lose potassium and retain sodium. This excess levels of sodium, increases the blood volume and blood pressure. The diagnosis and treatment of primary aldosteronism is important because it increases the risk of the heart diseases and stroke. This has provided the essential background for market growth. Factors such as increasing prevalence of primary aldosteronism and the growing geriatric population are the major drivers for the market growth. According to a study published in the International Journal of Endocrinology and Metabolism in 2016, the prevalence of the primary aldosteronism was estimated to be greater than 5%. Moreover, increasing obese population and rising consumption of alcohol is estimated to fuel the market. According to the World Health Organization, in 2016, approximately 1.9 billion adults aged 18 years or more were overweight. Moreover, it was estimated that out this population more than 650 million were obese. Additionally, rising per capita healthcare expenditure boosts the market growth. However, lack of awareness and risks associated with corrective surgeries like excessive bleeding, infection, anesthesia reaction besides others are estimated to restrain the market growth during the forecast period.

The global primary aldosteronism market is expected to grow at a CAGR of 8.40% during forecast period.
Segmentation

The global primary aldosteronism market is segmented on the basis of type, indications, diagnosis, treatment and end users.

On the basis of type, the market is segmented as Type I, and Type II. On the basis of indications, the market is categorized into heart attack, kidney failure, stroke, and others. On the basis of diagnosis, the market is segmented into blood test, imaging, and others. The blood test segment is sub-segmented into aldosterone profiling, renin profiling, and others. The imaging segment is sub-segmented into computed tomography (CT), positron emission tomography (PET), and others.On the basis of end users, the market is segmented into surgery, aldosterone antagonists, and others. The aldosterone antagonists is sub-m segmented into spironolactone, eplerenone, and others.
Key players for global primary Aldosteronism market

The key players for the global primary aldosteronism market are Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol Laboratories Ltd (England), CMP Pharma. (U.S.), Koninklijke Philips N.V. (The Netherlands), GE Healthcare (U.K), Siemens AG (Germany), Shimadzu Corporation (Japan), Canon Inc. (Japan), and others.